Provided by Tiger Trade Technology Pte. Ltd.

Taysha Gene Therapies, Inc.

6.27
-0.0300-0.48%
Pre-market: 6.380.1100+1.75%09:15 EDT
Volume:2.80M
Turnover:17.67M
Market Cap:1.80B
PE:-18.39
High:6.52
Open:6.25
Low:6.11
Close:6.30
52wk High:6.76
52wk Low:1.85
Shares:287.27M
Float Shares:185.00M
Volume Ratio:1.23
T/O Rate:1.51%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.3409
EPS(LYR):-0.3409
ROE:-68.45%
ROA:-27.42%
PB:7.29
PE(LYR):-18.39

Loading ...

Taysha Gene Therapies to Release First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 6

GlobeNewswire
·
Yesterday

Taysha Gene Therapies to present new TSHA-102 preclinical data at ASGCT annual meeting

Reuters
·
Apr 28

Taysha Gene Therapies announces annual shareholder meeting

Reuters
·
Apr 22

Unusually active option classes on open April 16th

TIPRANKS
·
Apr 16

U.S. Small Caps Finish Mixed As Taysha Gene Therapies Leads, BRP Lags

Dow Jones
·
Apr 16

Buy Rating on Taysha Gene Therapies Driven by Strong Leadership, Strategic Positioning, and Attractive Risk‑Reward Upside

TIPRANKS
·
Apr 15

Taysha Gene Therapies President Sukumar Nagendran disposes 200,000 shares for $892,000

Reuters
·
Apr 14

Taysha Gene Therapies Is Maintained at Buy by Canaccord Genuity

Dow Jones
·
Apr 06

Taysha Gene Therapies price target raised to $17 from $14 at Canaccord

TIPRANKS
·
Apr 06

Taysha grants 300,000 RSUs under Nasdaq inducement plan for new hires

Reuters
·
Apr 03

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Apr 03

Stock Track | Taysha Gene Therapies Soars 5.33% Intraday After Cantor Fitzgerald Issues Buy Rating

Stock Track
·
Mar 25

Taysha Gene Therapies (TSHA) Receives a Buy from Cantor Fitzgerald

TIPRANKS
·
Mar 25

Should Rett Breakthrough Status and Pivotal Trial Progress Require Action From Taysha Gene Therapies (TSHA) Investors?

Simply Wall St.
·
Mar 23

Taysha Gene Therapies (TSHA) Receives a Buy from Wells Fargo

TIPRANKS
·
Mar 22

Taysha Gene Therapies Advances Rett Program As Valuation Draws Investor Focus

Simply Wall St.
·
Mar 22

Taysha Gene Therapies Signals Momentum in Earnings Call

TIPRANKS
·
Mar 20

Taysha Gene Therapies Is Maintained at Buy by Chardan Capital

Dow Jones
·
Mar 20

Analysts Are Bullish on These Healthcare Stocks: Collegium Pharmaceutical (COLL), Taysha Gene Therapies (TSHA)

TIPRANKS
·
Mar 20

Chardan Capital Sticks to Their Buy Rating for Taysha Gene Therapies (TSHA)

TIPRANKS
·
Mar 20